枯草杆菌二联活菌肠溶胶囊联合常规保肝治疗急性肝损伤的疗效及卫生经济学评价

枯草杆菌二联活菌肠溶胶囊联合常规保肝治疗急性肝损伤的疗效及卫生经济学评价

陈耀明,施杨利,周柳柳

上海市第十人民医院崇明分院消化科邮编：202157#$NL;作者：陈耀明,男,本科,1970.2出生。消化科副主任医师#$NL研究方向：胃肠道肿瘤的早诊早治。yaoming1970@126.com#$NL单位电话：021-59418281,上海市第十人民医院崇明分院消化科邮编：202157#$NL;作者：陈耀明,男,本科,1970.2出生。消化科副主任医师#$NL研究方向：胃肠道肿瘤的早诊早治。yaoming1970@126.com#$NL单位电话：021-59418281,上海市第十人民医院崇明

收稿日期:2018-09-05 修回日期:2019-01-12 出版日期:2019-01-25
基金资助:
上海交通大学医学院科技基金项目（项目编号：09XJ22005；项目名称：消化道疾病的筛检方案）

Therapeutic Effect and Health Economics Evaluation of Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsule Combined with Conventional Liver Protection Treatment in Acute Hepatic Injury

CHEN Yaoming,SHI Yangli and ZHOU Liuliu

Department of Gastroenterology,Chongming Branch,Shanghai Tenth People''s Hospital Zip Code: 202157,Department of Gastroenterology,Chongming Branch,Shanghai Tenth People''s Hospital Zip Code: 202157,Department of Gastroenterology,Chongming Branch,Shanghai Tenth People''s Hospital Zip Code: 202157

Received:2018-09-05 Revised:2019-01-12 Online:2019-01-25

摘要/Abstract

摘要： 目的：探讨枯草杆菌二联活菌肠溶胶囊联合常规保肝治疗急性肝损伤的疗效及成本-效益情况。方法：将2015年1月至2017年12月我院消化内科收治的280例急性肝损伤患者按照随机数字表分为联合组（140例）和对照组（140例）。对照组给予常规保肝护肝治疗，包括B族维生素、保肝类药物，联合组在此基础上给予微生态制剂枯草杆菌二联活菌肠溶胶囊口服。两组疗程均为4周，定期复查肝功能。评估两组患者的临床疗效，比较两组患者的肝功能改善情况、不良反应及成本-效益。结果：治疗后，联合组总有效率为92.1%，高于对照组总有效率78.6% (P<0.05)。治疗4周后，两组患者血清天冬氨酸氨基转移酶（AST）、血清丙氨酸氨基转移酶（ALT）、总胆红素（TBIL）均较治疗前降低，联合组低于对照组(P<0.05)。联合组、对照组不良反应的发生率分别为10.7%、20.7%，两组比较差异有统计学意义(P<0.05)。联合组的平均成本高于对照组，但其总有效率、成本-效益比(C/E)均高于对照组。结论：枯草杆菌二联活菌肠溶胶囊联合常规保肝治疗急性肝损伤，通过纠正失调的肠道菌群状态从而更好地改善临床症状，促进肝功能恢复，减轻药物不良反应，且经济及社会效益高。

Abstract: Objective：To explore the therapeutic effect and cost-benefit of Bacillus subtilis and Enterococcus faecium enteric-coated capsule combined with conventional liver protection treatment in acute hepatic injury. Methods：A total of 280 patients with acute hepatic injury who received treatment in the department of gastroenterology from Jan 2015 to Dec 2017 were randomly divided into two groups according to random number table. The control group (n=140) was given conventional liver protection treatment， including vitamins B， liver-protective drugs. On this basis， the combined group was given Bacillus subtilis and Enterococcus faecium enteric-coated capsule orally. All the treatment courses were 4 weeks， liver function was regularly reviewed. The clinical efficacy of the two groups was evaluated， and the improvement of liver function， adverse reactions and cost-benefit of the two groups were compared. Results：After treatment， the total effective rate in the combined group was 92.1%， which was higher than 78.6% in the control group (P<0.05). After 4 weeks of treatment， liver function indexes such as AST， ALT， TBIL in both groups were lower than that before treatment， and the combined group was lower than that in the control group (P<0.05). The incidence of adverse reactions in the combined group and the control group was 10.7% and 20.7%， respectively. The difference between the two groups was statistically significant (P<0.05). The average cost of combined group was higher than that of the control group， but the total effective rate and C/E of the combined group were higher than those of the control group. Conclusion：Bacillus subtilis and Enterococcus faecium enteric-coated capsule combined with conventional liver protection treatment for acute hepatic injury can improve the clinical symptoms， promote the recovery of liver function， reduce the drug adverse reactions by correcting the imbalance of intestinal flora， and it has high economic and social benefits.

陈耀明,施杨利,周柳柳. 枯草杆菌二联活菌肠溶胶囊联合常规保肝治疗急性肝损伤的疗效及卫生经济学评价[J]. .

CHEN Yaoming,SHI Yangli and ZHOU Liuliu. Therapeutic Effect and Health Economics Evaluation of Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsule Combined with Conventional Liver Protection Treatment in Acute Hepatic Injury[J]. .

参考文献

[1] 郑锋玲,骆欢欢. 肠道菌群与慢性肝损伤关系的研究进展[J]. 中国微生态学杂志, 2014, 26(1):62-65.
[2] 郑三菊, 王崇慧, 占国清. 微生态制剂治疗肝硬化自发性细菌性腹膜炎疗效观察[J]. 中国微生态学杂志, 2014, 26(1):62-65.
[3] 王蕊.枯草杆菌肠球菌二联活菌联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝炎的疗效观察[J].安徽医药,2018,11(5):940-943.
[4] 赵广生,任志忠,刘影, 等.枯草杆菌二联活菌肠溶胶囊防治经肝动脉化疗栓塞术后不良反应及并发症的效果评价[J].临床肝胆病杂志,2016,15(1):88-91.
[5] Lo RS, Austin AS, Freeman JG.Is there a role for probiotics in liver disease? [J]. Scientific World Journal, 2014, 2014: 874768.
[6] 曹伟．益生菌对急性肝衰竭小鼠Notch信号通路的调控作用[D]．石家庄：河北医科大学,2014．
[7] 罗丹,江玉. 三七脂肝丸治疗非酒精性脂肪肝肝功能异常59例[J]．中国实验方剂学杂志,2014,20 (5) :202-204.
[8] 杨瑞园,赵新颜.肝组织病理学检查在药物性肝损伤诊治中的意义[J].临床肝胆病杂志,2018,9(6):1172-1175.
[9] 罗灵和,陈军贤,刘海燕, 等.枯草杆菌肠球菌二联活菌对非酒精性脂肪性肝炎患者的干预作用[J].中华消化杂志,2014,14(12):852-853.
[10] Malaguarnera G,Giordano M,Nunnari G,et al．Gut microbiota in alcoholic liver disease: Pathogenetic role and therapeutic perspectives[J]．World J Gastroenterol,2014,20 (44) :16639-16648.
[11] Wang YZ, Li YX, Xi JM, et al. Protective effects of probiotic Lactobacillus casei Zhang against endotoxin- and d-galactosamine-induced liver injury in rats via anti-oxidative and anti-inflammatory capacities[J]. Int Immunopharmacol, 2013, 15(1): 30-37.
[12] 夏俊.异甘草酸镁在化疗后肝功能异常治疗中的临床应用[J]．现代中西医结合杂志,2012,21 (9) :954-956.
[13] Frasinariu OE,Ceccarelli S,Alisi A,et al．Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: An input for novel therapies[J]．Dig Liver Dis,2013, 45(7): 543-551．
[14]曾勤.乳果糖联合枯草杆菌预防上消化出血后肝性脑病的临床疗效观察[J].中国医药指南,2012,8(31):551-552.
[15]王晓英,屈昌民,梁淑文, 等.枯草杆菌二联活菌治疗亚临床肝性脑病的临床研究[J].现代生物医学进展,2012,14(33):6489-6491.
[16]吕卉,秦来英,王灿, 等.枯草杆菌肠球菌二联活菌联合乳果糖治疗慢性重型肝炎内毒素血症的研究[J].中华消化杂志,2014,(12):850-851.
[17]Zhang Y, Wang L, Zhang J, et al. Probiotic Lactobacillus casei Zhang ameliorates high-fructose-induced impaired glucose tolerance in hyperinsulinemia rats[J]. Eur J Nutr, 2014, 53(17):221-232.
[18]郑小娟,郑海燕,罗灵和,等. 枯草杆菌二联活菌肠溶胶囊联合美沙拉嗪肠溶片对溃疡性结肠炎患者的临床研究[J]. 中国临床药理学杂志, 2016, 32(2):212-214.
[19]姚惠香,陈维雄,陈玮,等．益生菌治疗非酒精性脂肪性肝病的临床研究[J]．胃肠病学和肝病学杂志,2013,22( 3) : 221-223．
[20]Wang Y, Liu Y, Kirpich I, et al. Lactobacillus rhamnosus GG reduces hepatic TNFα production and inflammation in chronic alcohol-induced liver injury[J]. J Nutr Biochem, 2013, 24(12):1609-1615.

快速检索引用检索图表检索高级检索